Intellipharmaceutics International Inc. Quarterly Stockholders' Equity Attributable to Parent in USD from Q4 2010 to Q3 2023

Taxonomy & unit
us-gaap: CAD and USD
Description
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
Summary
Intellipharmaceutics International Inc. quarterly Stockholders' Equity Attributable to Parent history and growth rate from Q4 2010 to Q3 2023.
  • Intellipharmaceutics International Inc. Stockholders' Equity Attributable to Parent for the quarter ending August 31, 2023 was -$12.9M, a 26.8% decline year-over-year.
Stockholders' Equity Attributable to Parent, Quarterly (USD)
Stockholders' Equity Attributable to Parent, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2023 -$12.9M -$2.72M -26.8% Aug 31, 2023 6-K 2023-10-16
Q2 2023 -$12.9M -$3.02M -30.6% May 31, 2023 6-K 2023-10-16
Q1 2023 -$10.9M -$1.92M -21.3% Feb 28, 2023 6-K 2023-09-26
Q4 2022 -$10.6M -$2.42M -29.7% Nov 30, 2022 20-F/A 2024-02-06
Q3 2022 -$10.2M -$3.98M -64.6% Aug 31, 2022 6-K 2022-10-14
Q2 2022 -$9.86M -$4.83M -96% May 31, 2022 6-K 2023-10-16
Q1 2022 -$9.02M -$1.83M -25.5% Feb 28, 2022 6-K 2023-09-26
Q4 2021 -$8.16M -$1.84M -29.2% Nov 30, 2021 20-F/A 2024-02-06
Q3 2021 -$6.17M -$1.48M -31.7% Aug 31, 2021 6-K 2022-10-14
Q2 2021 -$5.03M +$779K +13.4% May 31, 2021 6-K 2022-07-21
Q1 2021 -$7.19M -$2.35M -48.7% Feb 28, 2021 6-K 2022-04-14
Q4 2020 -$6.31M -$2.62M -71% Nov 30, 2020 20-F/A 2024-02-06
Q3 2020 -$4.68M -$2.28M -94.6% Aug 31, 2020 6-K 2021-10-15
Q2 2020 -$5.81M -$4.8M -478% May 31, 2020 6-K 2021-07-15
Q1 2020 -$4.83M -$5.74M -633% Feb 29, 2020 6-K 2021-04-14
Q4 2019 -$3.69M -$7.79M -190% Nov 30, 2019 20-F/A 2024-02-06
Q3 2019 -$2.41M +$2.55M +51.5% Aug 31, 2019 6-K 2020-10-15
Q2 2019 -$1M +$25.8K +2.5% May 31, 2019 6-K 2020-07-15
Q1 2019 $907K +$3.63M Feb 28, 2019 6-K 2020-05-29
Q4 2018 $4.1M +$3.72M +962% Nov 30, 2018 20-F/A 2022-05-09
Q3 2018 -$4.96M -$4.17M -526% Aug 31, 2018 6-K 2019-10-11
Q2 2018 -$1.03M -$1.84M -228% May 31, 2018 6-K 2019-07-10
Q1 2018 -$2.72M Feb 28, 2018 6-K 2019-04-15
Q4 2017 $386K -$730K -65.4% Nov 30, 2017 20-F 2021-03-31
Q3 2017 -$793K Aug 31, 2017 6-K 2018-10-15
Q2 2017 $806K May 31, 2017 6-K/A 2018-07-24
Q4 2016 $1.12M +$1.25M Nov 30, 2016 20-F 2020-03-30
Q4 2015 -$138K -$5.05M -103% Nov 30, 2015 20-F 2016-03-21
Q4 2014 $4.91M +$10.9M Nov 30, 2014 20-F 2016-03-21
Q1 2014 $6.9M +$9.55M Feb 28, 2014 6-K 2014-04-14
Q4 2013 -$5.96M -$4.19M -237% Nov 30, 2013 20-F 2016-03-21
Q1 2013 -$2.65M Feb 28, 2013 6-K 2014-04-14
Q4 2012 -$1.77M +$1.33M +42.8% Nov 30, 2012 20-F 2016-03-21
Q4 2011 -$3.09M -$3.19M -3427% Nov 30, 2011 20-F 2015-02-27
Q4 2010 $93K Nov 30, 2010 20-F 2014-02-18
* An asterisk sign (*) next to the value indicates that the value is likely invalid.